Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted Against the Urokinase Receptor

Cancer Research - United States
doi 10.1158/0008-5472.can-08-2628
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity Against Gliomas With Increased Tumor Specificity

Cancer Research
Cancer ResearchOncology
2006English

High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus

Cancer Research
Cancer ResearchOncology
2004English

Oncolytic Herpes Virus Retargeted to HER-2

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

Specific Elimination of CD133+ Tumor Cells With Targeted Oncolytic Measles Virus

Cancer Research
Cancer ResearchOncology
2013English

Antitumor Efficacy of 34.5ENVE: A Transcriptionally Retargeted and “Vstat120”-Expressing Oncolytic Virus

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

A Novel Oncolytic Adenovirus Targeting to Telomerase Activity in Tumor Cells With Potent

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Measles Virus Selectively Blind to Signaling Lymphocyte Activation Molecule as a Novel Oncolytic Virus for Breast Cancer Treatment

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2012English

639. MicroRNA-Mediated Multi-Tissue-Detargeting of Oncolytic Measles Virus

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy